The estimated Net Worth of Dennis Mc Loughlin is at least $3.63 Million dollars as of 6 June 2023. Mr. Loughlin owns over 2,071 units of Pacira BioSciences Inc stock worth over $495,495 and over the last 6 years he sold PCRX stock worth over $608,863. In addition, he makes $2,527,710 as Chief Commercial Officer at Pacira BioSciences Inc.
Dennis has made over 6 trades of the Pacira BioSciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,071 units of PCRX stock worth $79,568 on 6 June 2023.
The largest trade he's ever made was selling 3,671 units of Pacira BioSciences Inc stock on 16 December 2019 worth over $168,095. On average, Dennis trades about 1,369 units every 163 days since 2018. As of 6 June 2023 he still owns at least 38,115 units of Pacira BioSciences Inc stock.
You can see the complete history of Mr. Loughlin stock trades at the bottom of the page.
Dennis McLoughlin serves as Chief Commercial Officer of the Company. He previously served as our Senior Vice President, Alliance Management from June 2018 until August 2018, our Vice President, Alliance Management from May 2017 to June 2018, our Executive Director, Alliance Management from January 2017 until May 2017, and as an Area Sales Director from December 2013 until January 2017. Prior to joining Pacira, he was President of Remedy Group, a pharmaceutical outsourcing company, from November 2003 until January 2014. Mr. McLoughlin holds a B.S. in Marketing from Saint Joseph's University.
As the Chief Commercial Officer of Pacira BioSciences Inc, the total compensation of Dennis McLoughlin at Pacira BioSciences Inc is $2,527,710. There are 2 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
Dennis McLoughlin is 54, he's been the Chief Commercial Officer of Pacira BioSciences Inc since 2018. There are 17 older and 7 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Dennis's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon, and Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: